Novo Nordisk has received accelerated approval for Wegovy, the first GLP-1 therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Raluca Ioana Draghici
International
www.shutterstock.com
Always see our news on Google
The FDA has fast-tracked approval of Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), affecting 5% of US adults. This is the first GLP-1 class therapy approved for MASH aimed at improving liver function. Preliminary studies have shown promising results, and Novo Nordisk has already applied for approval in Europe and Japan, expecting final trial results in 2029.
Sources
Latest News
10:03
The volume of construction works increased by 20% in June 2026 compared to the same month in 2025, and in the first six months, the advance was 13.9%.
10:02
Harry Kane has won the Golden Boot for the second time in his career, for the goals scored in the Bundesliga.
09:42
Save the Children and World Vision Romania request the Ministry of Education to maintain social scholarships and during the holidays.
09:29
Prince Harry and his wife Meghan plan to return to the United Kingdom to live in a private residence (British press)
09:15
Over 20,000 Russians have crossed the Russian-Georgian border in the last 24 hours, due to fears related to forced mobilization into war.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
